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understand differences in treatment patterns and outcomes among hemophilia A
patients between 2 developing countries, Philippines and Colombia, to identify
opportunities for improvement in hemophilia care. METHODS: We used a multi-
national, cross-sectional design to administer an IRB-approved paper-based sur-
vey to consenting hemophilia A patients 18 or caregivers for patients age 2-17 in
Philippines and Colombia (Inhibitor patients excluded). Patients were recruited
primarily through local hemophilia associations. Data collection occurred from
January to August 2011. Questions patients were asked include treatment regimen,
annual bleed rates(ABR) and health-related quality of life (HRQOL). HRQOL was
measured by the PEDS-QL for children, the SF-12 for adults and the EQ-5D for all
patients. RESULTS: 179 patients were surveyed overall, with 76 in the Philippines
and 103 in Colombia. 54% were adults in the Philippines, with 72% in Colombia. In
the Philippines, 59% of patients reported receiving either recombinant factor VIII
(FVIII) or plasma-derived FVIII while it is 100% in Columbia. 24% of patients in
Philippines reported receiving cryoprecipitate or fresh frozen plasma, which is
considered sub-standard care. 93% of patients in Colombia reported being on a
prophylaxis treatment regimen compared to 0% in Philippines. Colombia patients
had significantly lower median ABR compared to Philippines (8 vs.15, p.0006).
Accordingly, patients in Colombia also reported better mean EQ-5D scores com-
pared to Philippines patients (0.77 vs. 0.68, p.0001). CONCLUSIONS: Despite the
limited resources of a developing country, results suggest Colombia has an en-
hanced level of hemophilia care compared to the Philippines. Opportunities exist
for Philippines to improve patient access to appropriate care to achieve better
outcomes for their hemophilia A population
PSY20
INFLIXIMAB SIGNIFICANTLY IMPROVES SYMTOMS AND QUALITY OF LIFE IN
PATIENTS WITH ANKYLOSING SPONDYLITIS IN CHINA
Wang NS1, Bi LQ2, Chen JW3, He DY4, Wu LJ5, Lin J6, Yue N7, Li JG7, Feng WW7
1Shanghai No. 6People’s Hospital, Shanghai, China, 2China-Japan Union Hospital of Jilin
University, Changchun, China, 3No. 2Xiangya Hospital of Central South University, Changsha,
China, 4Shanghai Guanghua Hospital of Rheumatoid Arthritis, Shanghai, China, 5Sinkiang
People’s Hospital, Urumchi, China, 6First Affiliated Hospital of Zhejiang University, Hangzhou,
China, 7Johnson & Johnson, Beijing, China
OBJECTIVES: Ankylosing spondylitis (AS) is a chronic progressive autoimmune
inflammatory condition that affects the spine and sacroiliac joints causing pain
and stiffness in and around the spine. AS leads to irreversible structural changes
and consequently impairs spinal mobility and quality of life (QoL). The aim of our
studywas to evaluate the impact of anti-TNF therapy (Infliximab) on clinical symp-
toms and QoL in AS patients in China. METHODS: A multi-center study was con-
ducted from 2009 to 2011 in AS patients at 40 urban hospitals in 23 cities in China.
Comparisons were made between patients who were treated with Infliximab at
baseline and follow ups (experienced-Infliximab group, EIG) and those who were
not treated with Infliximab at baseline but went on Infliximab treatment at the
follow ups (new-Infliximab group, NIG). Clinical symptomsweremeasured by Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondy-
litis Functional Index (BASFI), and Bath Ankylosing Spondylitis Metrology Index
(BASMI). Short Form-12 (SF-12) scoring system was used to calculate the physical
and mental component summary scores (PCS, MCS). RESULTS: Total 644 AS pa-
tientswere identified (mean age29 years; 82.7%male). The average duration of AS
was 3 years, with almost 24% patients suffering AS more than 5 years. At baseline,
the mean scores reported from the patients in EIG were: BASDI 2.50, BASFI 1.85,
BASMI 1.71, MCS 48 and PCS 43, which were all significantly better than those in
NIG. After 12 weeks Infliximab treatment, NIG patients improved significantly in
BASDI (-2.97), BASFI (-2.11), BASMI (-1.79), MCS (-34.19) and PCS (-18.20) than base-
line (all P0.0001). CONCLUSIONS:AS patients using Infliximab have better quality
of life and daily function activities than those not using Infliximab before. The
findings of this study indicate a significant improvement in QoL of patients follow-
ing initiation of Infliximab therapy in China.
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OBJECTIVES: Psoriasis is a chronic, non-contagious disease characterized by in-
flamed lesions covered with silvery-white scabs of dead skin. This study aims to
evaluate the burden of psoriasis on patients in China. METHODS: This study was
conducted in psoriasis patients and dermatologists. Quantitative face-to-face in-
terviews were carried out with 135 dermatologists and 706 psoriasis patients in
eight cities located in northern, central and southern China. RESULTS: Dermatol-
ogists had an average patient load of 68 psoriasis patients permonth, of which 60%
had plaque psoriasis, 55% of those patients had moderate to severe plaque psori-
asis. Of psoriasis cases, patents were primarily aged between 36-55 years old, and
60%were female. Chinese dermatologists definedmoderate based on the BSA score
of 29-45% (vs. global criterion 3-10%) and severe based on the BSA score of 46% or
higher (vs. global 10%). More than half of the dermatologists felt that psoriasis
had an EXTREME impact on patients’ quality of life (QoL) due to mental and ap-
pearance injury. About 1/3 of the patients suffered from psoriasis-related co-mor-
bidities, with hypertension (8%), diabetes (7%), and psoriatic arthritis (5%) occur-
ringmost frequently. Fifty-six percent of the patientsmissed 6 working days in the
past 6 months due to psoriasis. Majority of the patients (81%) were treated as soon
as they were diagnosed. On average moderate patients had received 12 various
treatments previously, while severe patients had received over 18 different types of
treatment, however 86% patients were unsatisfied with their current treatments.
CONCLUSIONS: Psoriasis is underestimated and undiagnosed due to the more
stringent severity measurement criteria used in China. This study indicates that
psoriasis has a negative impact on patients both physically andmentally. Further-
more, majority of the patients are unsatisfied with existing treatments. Newer
treatments like biologics will address the unmet medical needs of psoriasis pa-
tients in China.
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